Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jerusalem
Clinical trial register · Israel

Clinical Trials in Jerusalem, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2438 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2438
Studies in scope
all four open statuses
1243
Recruiting now
open to new participants
461
Lead sponsors
across recruiting studies
Top sites
Haifa 94 Ramat Gan 86 Jerusalem 80 Petah Tikva 63 Tel Aviv 52
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC80 AbbVie64 AstraZeneca52 Janssen Research & Development, LLC46 Hadassah Medical Organization40 Clear sponsor filter
Site location
Haifa94 Ramat Gan86 Jerusalem80 Petah Tikva63 Tel Aviv52
All 24 locations
Target enrolment
to

Trials with a site in Jerusalem

80 of 2438 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Israel
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
380
Jerusalem
2026-10-21
Not yet open
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
NCT07709000Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
DrugsAvtozma·Tyenne·Siltuximab·MK-1045
Merck Sharp & Dohme LLC
Phase 2
60
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2026-10-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
Jerusalem, Ramat Gan, Tel Aviv
2026-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
340
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2026-05-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2026-05-04
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2026-05-03
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
Jerusalem, Kfar Saba, Ramat Gan
2026-04-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin
2026-04-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Hadera, Haifa, Jerusalem, Petah Tikva, Tel Aviv
2026-01-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Afula, Jerusalem, Tel Aviv
2025-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Beer Ya Akov, Jerusalem, Kfar Saba, Ramat Gan, Tel Aviv
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Beersheba, Haifa, Jerusalem, Ramat Gan
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2025-07-03
Recruiting
Merck Sharp & Dohme LLC
Phase 2
160
Afula, Jerusalem, Petah Tikva, Ramat Gan
2025-05-29
Recruiting
Merck Sharp & Dohme LLC
Phase 2
144
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Haifa, Jerusalem, Kfar Saba, Tel Aviv
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 2
96
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2025-05-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
2025-05-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Haifa, Holon, Jerusalem, Kfar Saba, Safed
2025-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
Haifa, Jerusalem, Petah Tikva, Ramat Gan
2025-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv
2025-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Hadera, Haifa, Jerusalem, Kfar Saba, Ramat Gan
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
90
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2025-03-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2025-03-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Haifa, Jerusalem, Petah Tikva, Ramat Gan
2025-02-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Haifa, Jerusalem, Tel Aviv, Tiberias
2025-01-27
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
Haifa, Jerusalem, Tel Aviv
2024-11-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Haifa, Jerusalem, Kfar Saba, Ramat Gan
2024-10-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Sakhnin, Tsrifin
2024-08-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Haifa, Holon, Jerusalem, Ramat Gan
2024-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
2024-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2024-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Haifa, Jerusalem, Petah Tikva, Ramat Gan
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2024-06-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Hadera, Haifa, Jerusalem, Petah Tikva, Tel Aviv
2024-05-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Haifa, Jerusalem, Petah Tikva, Ramat Gan
2024-04-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Haifa, Jerusalem, Petah Tikva, Ramat Gan
2024-04-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Afula, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Afula, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tsrifin
2023-12-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Haifa, Jerusalem, Petah Tikva
2023-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2023-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Ashkelon, Beersheba, Hadera, Haifa, Herzliya, Holon, Jerusalem, Majd el Kurūm
2023-10-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2023-08-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Afula, Jerusalem, Petah Tikva, Ramat Gan
2023-07-19
Active, closed
Merck Sharp & Dohme LLC
Phase 1
95
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2023-07-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
641
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2023-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
537
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2023-03-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
514
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2023-02-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Jerusalem, KfarSaba, Petah Tikva, Tel Aviv, Tsrifin
2023-02-06
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
60
Afula, Haifa, Jerusalem, Petah Tikva, Tel Aviv
2022-08-10
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Afula, Beersheba, Haifa, Jerusalem, Nahariya, Ramat Gan
2022-07-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
60
Jerusalem, Ramat Gan
2022-07-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Haifa, Jerusalem, Ramat Gan
2022-03-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2022-03-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
40
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2022-02-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Beersheba, Haifa, Holon, Jerusalem, Ramat Gan
2022-02-03
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Afula, Haifa, Jerusalem
2022-01-14
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Haifa, Jerusalem, Kfar Saba, Ramat Gan
2021-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Afula, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2021-12-13
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
110
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2021-08-19
Active, closed
Merck Sharp & Dohme LLC
Phase 2
730
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2021-08-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2021-05-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin
2021-04-21
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Afula, Beersheba, Haifa, Jerusalem, Ramat Gan, Rehovot, Tel Aviv
2021-04-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan
2021-01-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2020-05-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,033
Kfar Saba, Tel Aviv, Haifa, Jerusalem
2020-02-27
Recruiting
Merck Sharp & Dohme LLC
Observational
1,065
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
450
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-12-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Afula, Ashdod, Beersheba, Haifa, Jerusalem, Kfar Saba, Nazareth, Petah Tikva
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2018-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 2
329
Beersheba, Haifa, Jerusalem, Ramat Gan, Tel Aviv
2018-12-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Beersheba, Tel Aviv, Afula, Haifa, Jerusalem, Ramat Gan, Tsrifin
2018-09-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Afula, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv, Tsrifin
2018-08-21
Rows per page Showing 1–80 of 80
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-israel/city/jerusalem

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,438 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 80 of those studies with a site in Jerusalem that also match the filters currently applied.

How many clinical trials are recruiting in Jerusalem?

43 of the 80 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 36 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jerusalem), 80 studies
PhaseStudiesRecruitingShare
Phase 3502362.5%
Phase 214817.5%
Phase 1/29611.3%
Phase 2/3445%
Phase 1212.5%
Observational111.3%

Most active sponsors

Lead sponsors with the most studies (Jerusalem)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC8043
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.